David Booth says decades of public-market data should have earned a “ticker tape parade.” The harder question now: why investors keep moving toward private equity, where the evidence on risk and return is thinner. okt.to/vgsneu
Fidelity says nonprofits are considering higher spending even as fundraising stays under pressure and less is coming in from individual donations. The question is how long that can hold. okt.to/hivFI2
1
2
654
Lone Pine Capital replaced nine of its top ten holdings in the third quarter, including five new positions, after a sharp reversal in performance. What does Stephen Mandel Jr.'s reset signal? okt.to/Nz1bIo
2
2,951
October marked a painful month for many hedge funds, particularly the Tiger Cubs and Grandcubs, as substantial gains were erased, leaving some in the red. The tech sector's downturn exacerbated these losses. okt.to/YVNPwH
Michigan State’s Philip Zecher is treating trillion-dollar IPOs as an exception, not a new baseline. Anthropic’s planned listing is reviving the debate over whether private capital can keep pushing valuations higher. okt.to/80wMkz
1
729
When diversification fails, what’s truly alternative?
okt.to/9GMLy5
Sponsored by iM Global Partners
#InstitutionalInvesting #AlternativeInvestments #ManagedFutures #PortfolioDiversification
1
584
A sharp sell-off in AI and technology names spilled into health care, and Janus is pointing back to fundamentals in biotech. okt.to/EY6N5V
1
591
Wilshire is getting folded into Marsh’s broader push into advisor-led wealth, with wealth advisory, research and alternatives now in the mix. okt.to/hDUOYJ
1
683
Roughly 75 robotics companies have reached unicorn status in the past three years, and 45 did so this year alone. Hedge funds are increasingly showing up in the financing. okt.to/TIZzPV
1
611
PivotalPath’s early October read shows the strain hit market-neutral funds too: the Equity Market Neutral Index fell 2.48%, its worst October on record. okt.to/rmMUd3
523
As inflation, resource constraints, and geopolitical fragmentation reshape markets, diversification assumptions are being put to the test.
okt.to/3kG6cq
Sponsored by @AspectCapital
#InstitutionalInvesting #PortfolioConstruction #AssetAllocation
1
530
Only three companies are set to price this week, and all are health care names. The IPO market is still leaning on biopharma, even as investors wait for Anthropic later this month. okt.to/wrUigt
1
645
Research says the University of Illinois endowment could have been nearly $800 million larger. Leaders say the foundation has already overhauled the portfolio and are pressing that case now. okt.to/zW1X9l
1
520
Janus says the recent pullback in healthcare and biopharma could sharpen attention on fundamentals — and on entry points in high-quality biotech names. okt.to/Zts6ib
1
595
Marsh is buying Wilshire for its wealth advisory and alternatives capabilities, adding a broader institutional client base as advisory firms keep moving toward wealth and retail capital. okt.to/IOyXgJ
In Q3, global VC investment in robotics surged to $9.9 billion, more than double the previous year. This has led to 45 robotics firms achieving unicorn status in 2026 alone. What factors are driving this unprecedented growth? okt.to/mFyxq9
In October, market-neutral funds faced unexpected challenges, with the Equity Market Neutral Index dropping 2.48%, marking its worst October on record. What does this mean for future hedge fund strategies? okt.to/nXSrPA
Three IPOs are set to price this week, and all are health care-related. Biopharma is still carrying the IPO market, but the bigger question is how long that can last for allocators. okt.to/n8SkDP
1
1
1,082
Hedge funds often face criticism for high fees and underperformance, but a critical gap in data reporting is complicating investors' evaluations. How this missing data skews perceptions—and what it means for asset allocators—remains an open question. okt.to/LwtyMR
2
902



